New Launch7 Nov 2026, 12:30 pm
AstraZeneca Pharma India to launch Datverzo in November 2026
AI Summary
AstraZeneca Pharma India Ltd has announced the upcoming launch of its new drug, Datverzo (Datopotamab Deruxtecan), in India in November 2026. This follows the company's earlier intimation on December 17, 2025, regarding the receipt of Import and Market Permission in Form CT-20 from the Drugs Controller General of India. Datverzo is approved for treating specific types of advanced breast cancer in adult patients who have undergone prior endocrine-based therapy and chemotherapy.
Key Highlights
- Datverzo to be launched in India in November 2026.
- Drug received Import and Market Permission from DCGI.
- Indicated for advanced HR+/HER2- breast cancer treatment.
- Follows earlier communication dated December 17, 2025.
Price Impact
More from ASTRAZEN